FDA PCAC Day 2 Recap: Mixed Results for Emideltide, Epitalon, and Semax

The highly anticipated July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting has concluded. Following a historic Day 1 that saw the committee recommend easing restrictions on four major peptides — BPC-157, KPV, TB-500, and MOTS-c — the focus on Day 2 shifted to a different class of compounds. On July 24, the committee evaluated three neurologically and metabolically active peptides: Emideltide (DSIP), Epitalon, and Semax.

The tone of the second day was markedly different. While Day 1 felt like a unified pushback against blanket FDA restrictions, Day 2 demonstrated that the committee was willing to draw lines in the sand when the clinical evidence — or the lack thereof — demanded it.

The final tally for the day: two peptides were recommended for inclusion on the 503A Bulks List, and one was voted down.

Here is a detailed breakdown of the FDA's arguments, the committee's rationale, and the final votes for Emideltide, Epitalon, and Semax.

The Regulatory Backdrop

As a reminder, the PCAC was convened to advise the FDA on whether to include these seven nominated peptides on the Section 503A Bulks List. Inclusion on this list creates a federal pathway for state-licensed compounding pharmacies to legally prepare patient-specific medications using these bulk drug substances.

The FDA career staff entered both days of the meeting with a unified stance: they recommended against adding any of the seven peptides to the list, citing a lack of rigorous, large-scale clinical trials demonstrating safety and efficacy, as well as concerns about chemical standardization. [1]

On Day 1, the committee largely rejected the FDA's cautious approach, arguing that the absence of perfect data does not equate to a lack of clinical utility, and that restricting access only drives patients to dangerous, unregulated gray markets. [2]

On Day 2, however, the FDA's arguments regarding safety and evidence quality resonated more strongly with several panel members, leading to tighter votes and one outright rejection.

The Votes: Epitalon, Semax, and Emideltide

### Epitalon (Epithalon)

The Vote: 7–4 in favor (1 abstention) [3]

Epitalon is a synthetic tetrapeptide based on a natural peptide extracted from the pineal gland. In clinical and longevity circles, it is primarily discussed for its potential to regulate the sleep-wake cycle, increase melatonin production, and potentially influence telomerase activity. The FDA specifically reviewed Epitalon (both free base and acetate forms) for the treatment of insomnia.

The FDA staff argued that there was insufficient evidence to support its effectiveness for insomnia, pointing to a lack of robust clinical trial data. [4]

However, the PCAC members appeared more confident in the safety profile and clinical utility of Epitalon. Many panelists argued that the ultimate determination of safety and efficacy for a compound like Epitalon should remain a discussion between a doctor and their patient.

Dr. Gabriel Alizaidy of Maximus Health, who voted in favor of Epitalon, pointed out a significant disconnect between the FDA's presentation and clinical reality, noting that there was an "immense" mismatch between the real-world data on the peptide's use and what the FDA had presented. [1]

Ultimately, the committee voted 7 to 4 to recommend adding Epitalon to the 503A Bulks List. [3]

### Semax

The Vote: 8–5 in favor [3]

Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH). It has been approved and used clinically in Russia for decades, primarily for its neuroprotective and cognitive-enhancing properties. The FDA evaluated Semax for the treatment of migraines, cerebral ischemia (reduced blood flow to the brain), and trigeminal neuralgia (a severe chronic pain condition). [4]

During the public comment period, Semax received vociferous support. Advocates highlighted that, unlike some other peptides on the docket, Semax has a substantial body of international clinical data due to its approved status in Russia. [3]

Despite this, the FDA maintained that their review of the available research found the evidence insufficient to support its use for the specific conditions under review, and stated that a "balancing of the criteria weighs against" expanding access. [4]

The committee disagreed with the agency's conclusion. Recognizing the neuroprotective potential of the peptide and the volume of international data, the panel voted 8 to 5 to recommend adding Semax to the compounding list. [3]

### Emideltide (Delta Sleep-Inducing Peptide / DSIP)

The Vote: 6–7 against (1 abstention) [1]

Emideltide, widely known as Delta Sleep-Inducing Peptide (DSIP), was the only peptide to be rejected by the committee over the two-day meeting. It is a nonapeptide that has been studied for its potential to promote sleep and manage stress. The FDA evaluated it for the treatment of chronic insomnia, narcolepsy, and opioid withdrawal. [4]

The FDA presented a strong case against Emideltide. They noted that the clinical studies used to support its efficacy for narcolepsy consisted of a single patient case report, and the data for opioid withdrawal relied on two small, uncontrolled studies. [5] Furthermore, these studies utilized an intravenous route of administration, whereas the compounded versions sought by patients are typically subcutaneous injections or nasal sprays. [5]

The agency also raised significant safety concerns, arguing that the peptide is not well characterized, its purity profile cannot be easily confirmed, and inconsistent naming standards pose serious patient safety risks. [1] Finally, the FDA pointed out that well-tested, FDA-approved treatments already exist for all of the proposed indications. [5]

These arguments swayed several committee members who had previously voted in favor of other peptides. Dr. Todd Durham, SVP of clinical and outcomes research at the Foundation Fighting Blindness, explained his 'no' vote by citing the "low-quality evidence around efficacy, the poor characterization of the bulk drug substance and the fact that there are approved medical therapies for all proposed uses." [1]

David Pope, Chief Pharmacy Officer at XiFin Pharmacy Solutions, who had been a vocal proponent of access on Day 1, also voted against Emideltide, expressing concern over its "potentially dangerous downstream consequences." [3]

The final tally was 6 votes in favor, 7 against, and 1 abstention — meaning the committee will advise the FDA not to add Emideltide to the 503A Bulks List. [1]

Summary of the Two-Day Meeting

Over the course of July 23 and 24, the PCAC evaluated seven highly sought-after peptides. The final scorecard represents a meaningful shift in the regulatory conversation surrounding peptide therapies.

What Happens Next?

It is vital to reiterate that the PCAC votes are advisory and non-binding. The FDA is not legally obligated to follow the committee's recommendations.

The agency must now review the meeting records, the public comments, and the official votes. If they choose to adopt the committee's advice — which they historically do, though the current political climate makes predictions difficult — they will publish proposed rules and open them for public feedback. This rulemaking process can take up to a year. [5]

However, the fact that six out of seven peptides received positive recommendations is a watershed moment for compounding pharmacies and patients. It signals a growing recognition among medical experts that these compounds have legitimate clinical utility, and that pushing patients into the unregulated gray market is a failure of public health policy.

The rejection of Emideltide also demonstrates that the committee was not simply rubber-stamping every nomination. They evaluated the evidence, weighed the risks, and drew a line when the data was deemed too weak or the safety profile too uncertain. This level of discernment actually lends credibility to their positive votes for the other six peptides.

The peptide landscape is evolving rapidly. While we await the FDA's final ruling, the results of this PCAC meeting offer a clear reason for cautious optimism. Sensible regulation and expanded access appear to be on the horizon.

References

[1] Kansteiner, F. (2026, July 24). *Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback*. Fierce Pharma. https://www.fiercepharma.com/pharma/peptide-adcomm-day-2-emideltide-voted-down-panels-1st-peptide-pushback

[2] Jewett, C., & Smith, D. G. (2026, July 24). *F.D.A. Panel's Vote on Peptides Raises Concerns About a Prescribing Boom*. The New York Times. https://www.nytimes.com/2026/07/24/us/politics/fda-panel-vote-peptides.html

[3] Lawrence, L., & Todd, S. (2026, July 24). *FDA advisory panel narrowly rejects compounding of one peptide, backs two others*. STAT News. https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/

[4] Smith-Schoenwalder, C. (2026, July 24). *FDA Panel Wants to Expand Access for These 6 Peptides*. U.S. News & World Report. https://www.usnews.com/news/national-news/articles/2026-07-24/fda-committee-votes-on-7-peptides-what-are-they

[5] Daniel, Y. (2026, July 24). *FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?* ABC News. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915